Search Results

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the first quarter period ended March 31, 2024.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product discovery and development, announced that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.

Evogene Ltd. today announced its financial results for the fourth quarter and full-year period ending December 31, 2023.

Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunityPatrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors

Evogene Ltd announced today that it will release its financial results for the third quarter of 2023 on Thursday, March 7th, 2024.

Evogene Ltd today announced its financial results for the third quarter period ended September 30, 2023.

Evogene Ltd. reported that the Company received a letter from the Nasdaq Stock Market LLC, indicating that the Company is currently not in compliance with Nasdaq Rule 5550, as the Company’s closing bid price for its ordinary shares has been below $1.00 per share for the last 30 consecutive business days.